![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Thursday, August 15, 2013 7:44:57 AM
1- A person (host) that is unwell goes to the clinic/physician
2- He/She is diagnosed as being a host to a life-threatening virus
3- The virus is attacking host target-cells, replicating and continuing the attack
4- The host's immune system is mounting an offensive but it is being overwhelmed by the high number of virus "replicants"; it needs help and quick
5- The physician prescribes a dose (or two) of the necessary "nano-Cide" to do combat with the replicating virus (replicants)
6- One dose of the "nano-Cide" has approximately 75 trillion bio-mimetic "nano-Terminators" (imitate virus target cells) and it is injected into, or orally taken by, the host. They are also anphiphilic (water-loving) so they go to 50-75% of your body, depending on how hydrated the host is.
7- The "nano-Terminators" start to circulate in the host's blood stream at the speed of heart beats.
8- The virus (replicant) bumps into and engages one of trillions of "nano-Terminators" in the host. The "nano-Terminator" asks the replicant, who is your daddy and what does it do?, as it proceeds to engulf the "replicant". The "nano-Terminator" defeats the virus "replicant".
9- At the speed of heartbeats more virus "replicants" bump and engage other "nano-Terminators" and as expected the virus "replicants" come to their end, in the trillions, in a matter of hours.
10- The odds for the host's immune system are now better and continues to do battle against whatever is left of the virus "replicant" army, if any, and finish it.
11- The host grabs a tissue to wipe his/her nose clean. He/she is feeling a lot better and ready to go about their daily business.
Recent NNVC News
- NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • InvestorsHub NewsWire • 05/02/2024 02:07:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 09:53:32 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/14/2024 09:55:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/19/2024 09:44:48 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 12/04/2023 09:08:49 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 10/13/2023 08:30:41 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 09/28/2023 08:44:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/01/2023 08:46:45 PM
- Clinical Trial of Broad-Spectrum Antiviral Drug NV-CoV-2 is Progressing Well, Says NanoViricides - NV-CoV-2 is Positioned to Fulfill Many Unmet Medical Needs • InvestorsHub NewsWire • 07/06/2023 03:16:37 PM
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM
ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM